Kartalis Athanasios, Didagelos Matthaios, Georgiadis Ioannis, Benetos Georgios, Smyrnioudis Nikolaos, Marmaras Haralambos, Voutas Petros, Zotika Christina, Garoufalis Stefanos, Andrikopoulos Georgios
Cardiology Department, 'Skylitseio' General Hospital of Chios, Greece
Cardiology Department, 'Skylitseio' General Hospital of Chios, Greece.
Eur J Prev Cardiol. 2016 May;23(7):722-9. doi: 10.1177/2047487315603186. Epub 2015 Aug 26.
Chios mastic gum (CMG) possesses anti-oxidant, anti-inflammatory, anti-atheromatic, lipid- and glucose-lowering properties. We evaluated the effects of CMG on cholesterol and fasting plasma glucose (FPG) levels of healthy volunteers.
A prospective, randomized, placebo-controlled, pilot study.
One hundred and seventy nine volunteers with total cholesterol levels >200 mg/dl were randomized to four groups. Finally, 156 volunteers completed the follow-up period and were analysed: (1) control group (C, n = 23), receiving placebo; (2) total mastic (TM, n = 72) receiving daily a total dose of 1 g of crude CMG (330 mg capsules, tid); (3) polymer-free mastic (PFM, n = 33), receiving daily a total dose of 1 g of polymer free mastic (330 mg caps, tid); and (4) powder mastic (PM, n = 28), receiving daily a total dose of 2 g of crude CMG.
After eight weeks, the TM group reduced total cholesterol by 11.5 mg/dl (p < 0.05) and FPG by 4.5 mg/dl (p < 0.05) adjusted for age, gender, BMI and baseline characteristics. The effect was stronger in overweight and obese patients (BMI > 25), with an estimated mean reduction of total cholesterol by 13.5 mg/dl (p < 0.05) and FPG by 5.1 mg/dl (p < 0.05). Administration of PFM and PM resulted in no statistically significant alteration. No effect was observed on LDL, HDL, triglycerides, uric acid and CRP. No gastrointestinal, liver or renal adverse events were recorded.
CMG has a significant lowering effect on total cholesterol and glucose levels of healthy volunteers, with excellent tolerance and no detectable side effects, especially in overweight and obese individuals.
希俄斯乳香（CMG）具有抗氧化、抗炎、抗动脉粥样硬化、降血脂和降血糖特性。我们评估了CMG对健康志愿者胆固醇和空腹血糖（FPG）水平的影响。
一项前瞻性、随机、安慰剂对照的试点研究。
179名总胆固醇水平>200mg/dl的志愿者被随机分为四组。最后，156名志愿者完成了随访期并接受分析：（1）对照组（C，n = 23），接受安慰剂；（2）全乳香组（TM，n = 72），每日接受1g粗制CMG的总剂量（330mg胶囊，每日三次）；（3）无聚合物乳香组（PFM，n = 33），每日接受1g无聚合物乳香的总剂量（330mg胶囊，每日三次）；（4）乳香粉组（PM，n = 28），每日接受2g粗制CMG的总剂量。
八周后，经年龄、性别、BMI和基线特征调整后，TM组总胆固醇降低了11.5mg/dl（p<0.05），FPG降低了4.5mg/dl（p<0.05）。在超重和肥胖患者（BMI>25）中效果更强，估计总胆固醇平均降低13.5mg/dl（p<0.05），FPG降低5.1mg/dl（p<0.05）。给予PFM和PM未导致统计学上的显著变化。未观察到对低密度脂蛋白、高密度脂蛋白、甘油三酯、尿酸和C反应蛋白的影响。未记录到胃肠道、肝脏或肾脏不良事件。
CMG对健康志愿者的总胆固醇和血糖水平有显著降低作用，耐受性良好且未检测到副作用，尤其是在超重和肥胖个体中。
